Evidence map›Paper›PMID 41083764›Full record

ArticleThe AAPS journal2025

Affinity Capture Elution Coupled with Cell-based Cyclic Adenosine Monophosphate Assay as a Platform Method for Detection of Neutralizing Antibodies to Incretin Molecules.

Nichole A Reynolds, Yan Q Chen, Richard E Higgs, Boris Calderon, Jeff W Cramer, Nicoletta Bivi, Michael E Hodsdon, Heather A Bullock, Travis E Shockley, Victoria L Peek and 7 more

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in The AAPS journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors.

Nichole A ReynoldsLilly Research Laboratories, Eli Lilly and Company, 893 Delaware Street, Indianapolis, Indiana, 46225, USA.ORCID 0009-0005-3592-032X
Yan Q ChenLilly Research Laboratories, Eli Lilly and Company, 893 Delaware Street, Indianapolis, Indiana, 46225, USA.ORCID 0000-0001-9311-6077
Richard E HiggsLilly Research Laboratories, Eli Lilly and Company, 893 Delaware Street, Indianapolis, Indiana, 46225, USA.ORCID 0000-0003-0162-4109
Boris CalderonLilly Research Laboratories, Eli Lilly and Company, 893 Delaware Street, Indianapolis, Indiana, 46225, USA.ORCID 0000-0003-1575-0739
Jeff W CramerLilly Research Laboratories, Eli Lilly and Company, 893 Delaware Street, Indianapolis, Indiana, 46225, USA.ORCID 0009-0006-7978-6035
Nicoletta BiviLilly Research Laboratories, Eli Lilly and Company, 893 Delaware Street, Indianapolis, Indiana, 46225, USA.ORCID 0000-0003-1238-3822
Michael E HodsdonLilly Research Laboratories, Eli Lilly and Company, 893 Delaware Street, Indianapolis, Indiana, 46225, USA.ORCID 0009-0000-6910-1836
Heather A BullockLilly Research Laboratories, Eli Lilly and Company, 893 Delaware Street, Indianapolis, Indiana, 46225, USA.ORCID 0009-0003-3640-4525
Travis E ShockleyLilly Research Laboratories, Eli Lilly and Company, 893 Delaware Street, Indianapolis, Indiana, 46225, USA.ORCID 0009-0003-5204-2034
Victoria L PeekLilly Research Laboratories, Eli Lilly and Company, 893 Delaware Street, Indianapolis, Indiana, 46225, USA.ORCID 0009-0004-0206-5200
Justin K MackLilly Research Laboratories, Eli Lilly and Company, 893 Delaware Street, Indianapolis, Indiana, 46225, USA.ORCID 0009-0009-3593-4536
Deven LemenLilly Research Laboratories, Eli Lilly and Company, 893 Delaware Street, Indianapolis, Indiana, 46225, USA.ORCID 0009-0004-4131-9760
Victoria CopelandLilly Research Laboratories, Eli Lilly and Company, 893 Delaware Street, Indianapolis, Indiana, 46225, USA.ORCID 0009-0006-2685-2246
Andrea FerranteLilly Research Laboratories, Eli Lilly and Company, 893 Delaware Street, Indianapolis, Indiana, 46225, USA.ORCID 0009-0009-2788-9202
Robert J KonradLilly Research Laboratories, Eli Lilly and Company, 893 Delaware Street, Indianapolis, Indiana, 46225, USA.ORCID 0000-0003-0923-0542
Garrett MullinsLilly Research Laboratories, Eli Lilly and Company, 893 Delaware Street, Indianapolis, Indiana, 46225, USA. mullins_garrett@lilly.com.ORCID 0009-0000-5320-1023
Yi WenLilly Research Laboratories, Eli Lilly and Company, 893 Delaware Street, Indianapolis, Indiana, 46225, USA. wen_yi1@lilly.com.ORCID 0000-0003-4862-6427

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Formation of anti-drug antibodies (ADA) and, in particular, neutralizing antibodies (NAb), is a major risk to the development of biotherapeutics. Cell-based assays, which can reflect the mechanistic interactions among the drug, target, and NAb, are often most suitable for the detection of NAb. We report the development and validation of cell-based platform assays for a class of incretin molecules. An affinity capture elution step was employed to improve drug tolerance of a cell-based cyclic adenosine monophosphate (cAMP) assay. Assay conditions and procedures, including acid elution, cell density, and TAG labeled cAMP (cAMP-TAG) incubation time and concentration, were thoroughly optimized. Delta percent (Δ%) Neutralization was used to reduce assay variability during validation and sample analysis. This platform method has been applied to several incretin molecules and has demonstrated desired sensitivity, drug tolerance, and robustness.

Indexed as

Antibodies, NeutralizingCyclic AMPIncretinsAnimalsHumansAntibodies, NeutralizingCyclic AMPIncretinsAffinity capture elutioncAMP assayCell-based assayImmunogenicityIncretinNeutralizing antibodies

Identifiers

PMID41083764

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.